EWTX - Edgewise Therapeutics to Present at Upcoming Investor Conferences

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today that members of its senior management team will participate in fireside discussions and one-on-one investor meetings at two upcoming investor conferences:

BofA Securities 2022 Healthcare Conference
Fireside chat: Tuesday, May 10, 2022 at 8:40 am PT (11:40 am ET)

RBC Capital Markets Global Healthcare Conference
Fireside chat: Wednesday, May 18, 2022 at 3:35 pm ET

The presentations will be webcast live under the Edgewise events page and will be accessible for replay following the presentations. It is recommended that users connect to the webcasts several minutes prior to the start to ensure a timely connection.

About Edgewise Therapeutics

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare neuromuscular and cardiac disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle-focused drug discovery platform. Edgewise’s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn , Twitter and Facebook .

View source version on businesswire.com: https://www.businesswire.com/news/home/20220503005013/en/

Investors & Media
Michael Carruthers
Chief Financial Officer
ir@edgewisetx.com